Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123935) titled 'A Clinical Trial of Cationic Peptide-IL22BP mRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors' on May 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Metastatic Solid Cancer
Intervention:
25µg Dose Group:Intratumoral injection of IL-22BP gene preparation, 25µg per dose, total 5 doses, with 1-week interval between doses
50µg Dose Group:Intratumoral injection of IL-22BP gene preparation, 50µg per dose, total 5 doses, with 1-week interval between...